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Purpose: This study is to investigate the estrogen receptor β (ERβ) expression in molecular subtypes of breast
cancer and clinic significance of ERβ expression.
Method: The ERβ expression was detected in 730 cases of breast cancer tissue specimens by immunohistochemistry.
Twenty-one patients were censored during 2–10 years follow-up. The difference in ERβ expression was analyzed by
Pearson Chi-square Test. Its correlation with estrogen receptor α (ERα), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (Her-2) was analyzed by Spearman rank correlation. The accumulative tumor-free
survival rate was calculated by Kaplan-Meier method and difference in survival rate was analyzed by Log-rank test. Cox
regression was used for multi-factor analysis.
Result: The ERβ expression was significantly different among the molecular subtypes of breast cancer (P < 0.05). The
ERβ expression in breast cancer was positively correlated with Her-2 (P < 0.05) while it had no correlation with ERα and
Her-2. The expression of ERα was negatively correlated with Her-2 (P < 0.01) whereas positively correlated with PR
(P < 0.01). The expression of PR was negatively correlated with Her-2 (P < 0.05). The tumor-free survival rate in patients
with positive ERβ expression was significantly lower than that in patients with negative ERβ expression.
Conclusion: Positive ERβ expression is a poor prognostic factor of breast cancer.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1084557586106833
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Estrogen receptor (ER) and progesterone receptor (PR)
are steroid hormone receptors that belong to the nuclear
receptor superfamily. Clinically, ER and PR are hormone
dependent receptors of cancer cells. The human epidermal
growth factor receptor 2 gene (Her-2) encodes a trans-
membrane receptor-like protein, which has tyrosine kinase
activity. ER, PR and Her-2 play important roles in progno-
sis of breast cancer. There are two types of ER, which are
ERα and ERβ. ERβ was cloned in 1996 by Kuiper et al. [1]
from the cDNA library of rat prostate and ovary. ERα and
ERβ both play important roles in regulating the biological
function of the estrogen [2]. It is reported that ERβ has
prognostic value in breast cancer [3,4]. For example,* Correspondence: gejsy318@126.com
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reproduction in any medium, provided the orJensen et al. [5] reported that ERβ expression was closely
related to tumor growth and invasion of breast cancer and
was a prognostic factor for breast cancer.
Based on genetic profiles of ERα, PR and Her-2, Perou
et al. [6] proposed the molecular subtypes of breast cancer
in 2000, which included the luminal subtype, Her-2 over-
expression type, basal-like type and normal breast-like
type. In 2003, Sorlie et al. [7] further divided the luminal
subtype into luminal A type and luminal B type. It is well-
known that molecular subtypes are closely related to breast
cancer prognosis. Luminal subtype of breast cancer has
better prognosis than other subtypes and luminal A sub-
type has the best prognosis of all molecular subtypes [8].
However, in clinical practice, expression of ER, PR and
HER-2 evaluated by immunohistochemistry are used to
identify various breast cancer subtypes. Evidence indicates
that subtypes of breast cancer identified by DNA micro-
array may approximately relate to expression of commonly. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9]. Moreover, immunohistochemistry is much easier and
cheaper than gene microarray, but provides significant in-
formation to discriminate good and poor prognosis breast
cancer [10-12]. Thus, we used expression of ER, PR and
HER-2 to identify molecular subtypes of breast cancer in
this study.
In this study, the ERβ expression was examined by im-
munohistochemical staining in 730 cases of breast cancer.
The ERβ expression was analyzed in different molecular
subtypes of breast cancer. And the correlation of ERβ with
ERα, PR and Her-2 was also studied. Additionally, the ac-
cumulative tumor-free survival rate of breast cancer pa-
tients with different expression levels of ERβ was further
compared. Moreover, the prognostic role of ERβ in breast
cancer was evaluated by Cox regression analysis.Materials and methods
Samples
Seven hundred and thirty cases of patients with pathologic-
ally confirmed breast cancers were enrolled in this study.
They were all diagnosed and treated in the First Affiliated
Hospital of Xinjiang Medical University from January 2000
to December 2010. They had invasive ductal carcinoma,
with clinical stages of stage 0, stage I and stage II. Their
clinical data were complete and were shown in Table 1.
The patients were followed up for 2 to 10 years. During the
follow-up time, 21 patients were censored. Patients died of
other diseases, lost to follow-up at the time of last contact
or before study cut-off were censored.
Prior written and informed consent was obtained from
every patient and the study was approved by the ethics
review board of Xinjiang Medical University.Table 1 Clinical data of breast cancer patients used in
this study (n (%))
Clinical features Cases (%) Clinical features Cases (%)
Menses Staging
Menostasis 355 (50.1) Stage 0 218 (30.7)
Non-menostasis 354 (49.9) Stage 1 339 (47.8)
Age (years) Stage 2 152 (21.4)
≤ 39 164 (23.1) Chemotherapy
≥ 40 ~ 59 399 (56.3) Yes 595 (83.9)
≥ 60 146 (20.6) No 114 (16.1)
Tumor size (cm) Radiotherapy
≤ 2 329 (46.4) Yes 454 (64.0)
> 2 – ≤ 3 380 (53.6) No 255 (36.0)
Lymph node metastasis Endocrine therapy
L0 385 (54.3) Yes 290 (40.9)
L1~4 324 (45.7) No 419 (59.1)Immunohistochemical staining
Breast cancer tissue specimens were fixed in 10% formal-
dehyde for 24 h and then embedded in paraffin. Tissue
specimens were sliced into 3 um sections and placed in a
70°C oven overnight. Sections were then dewaxed in xy-
lene for 20 min and rehydrated in graded alcohols. En-
dogenous peroxidase was blocked by using a 3% solution
of hydrogen peroxide for 10 min. For antigen retrieval,
sections were placed in EDTA antigen retrieval solu-
tion and boiled for 20 min. After naturally cooling to
room temperature and washing with PBS, sections
were incubated with primary antibodies of polyclonal
rabbit anti-human ERβ antibody (BY-02101, Shanghai
Yueyan Biological Technology, CO., Ltd., Shanghai,
China), monoclonal rabbit anti-human ERα antibody
(ZA-0102, Beijing Zhong Shan-Golden Bridge Biological
Technology CO., Ltd., Beijing, China), monoclonal
rabbit anti-human PR antibody (ZA-0255, Beijing
Zhong Shan-Golden Bridge Biological Technology CO.,
Ltd., Beijing, China) and monoclonal rabbit anti-human
Her-2 antibody (4B5, Ventana Medical Systems Inc.,
Tuscon, Arizona, USA) at 37°C for 1 h in the dark. Then
sections were incubated with secondary antibodies of
HRP conjugated anti-rabbit IgG at 37°C for 30 min in
the dark. After antibody incubation, sections were de-
veloped with DAB chromogenic reagent for 5 min and
counterstained with haematoxylin. After hydrochloric acid
differentiation and dehydration in graded alcohols, sec-
tions were mounted with neutral gum. Positive samples
were used as the positive controls. In the negative con-
trols, the secondary antibodies were replaced with PBS.
Determination of ERβ, ERα, PR and Her-2 expression levels
The immunohistochemical staining results were evaluated
by an experienced pathologist. Cells with brown staining
were ERβ positive cells. Five fields at high-magnification
were randomly taken. ERβ positive rate was the ratio of
the number of ERβ positive cells to the total number of
cells in each field. ERβ positive rate less than 1% was de-
fined as ERβ negative (ERβ (−)). A positive rate between
1% and 10% was defined as ERβ weak positive (ERβ (+)).
ERβ positive rate between 10% and 50% was defined as
ERβ positive (ERβ (++)). ERβ positive rate over than 50%
was ERβ strong positive (ERβ (+++)).
ERα and PR positive cells were also stained brown.
According to the “Guideline Recommendations for Im-
munohistochemical Testing of Estrogen and Progester-
one Receptors in Breast Cancer” published by American
Society of Clinical Oncology (ASCO) and College of
American Pathologists (CAP) in 2010, a positive stain-
ing rate of > 1% was considered positive expression.
Based on “Her-2 Detection Guide” published by Chinese
Journal of Pathology in 2009, positive staining of Her-2
was defined as: 0, no staining; 1+: weak or incomplete cell
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showing weak to moderate intensity with complete but
nonuniform membrane staining or < 30% of invasive can-
cer cells showing strong, complete and uniform mem-
brane staining; 3+: > 30% of invasive cancer cells showing
strong, complete and uniform membrane staining.Statistical analysis
SPSS17.0 software was used for statistical analysis. Ex-
pression difference was analyzed by Pearson chi-square
test and correlation among different expressions was
assessed by Spearman’s Rank-order correlation. The ac-
cumulative tumor-free survival rate was calculated using
the Kaplan-Meier method. The difference in tumor-free
survival between groups with different ERβ expression
was compared by Log-rank test. Analysis of multivariate
prognostic factors was performed by Cox regression
model. P < 0.05 was considered statistically significant.Results
ERβ, ERα, PR and Her-2 expression in breast cancer
To determine the expression of ERβ, ERα, PR and Her-2
in breast cancer tissue, immunohistochemical staining was
performed. Representative results were shown in Figure 1.
Cells with brown granules were positively stained. As de-
scribed in “Materials and Methods”, ERβ expression levels
were divided into ERβ (−) (Figure 1A), ERβ (+) (Figure 1B),
ERβ (++) (Figure 1C) and ERβ (+++) (Figure 1D). ERα
negative and positive expression was shown in Figure 1E
and Figure 1F. PR negative and positive expression was
shown in Figure 1G and Figure 1H. Her-2 negative and
positive expression was shown in Figure 1I and Figure 1J.Figure 1 Expression analysis of ERβ, ERα, PR and Her-2 in breast canc
and Her-2 expression. Representative images were shown. Cells with brown g
(ERβ (−)). (B) ERβ weak positive expression tissue (ERβ (+), cancer cells with a
cells with a positive rate between 10% and 50%). (D) ERβ high expression tiss
tissue. (F) ERα positive tissue. (G) HR negative tissue. (H) HR positive tissue. (I)Molecular subtypes of breast cancer were defined based
on the expression levels of ERα, PR and Her-2.
ERβ expression is significantly different in different
molecular subtypes of breast cancer
To compare the difference in ERβ expression among differ-
ent molecular subtypes of breast cancer, we did Pearson
chi-square test. Firstly, the molecular subtypes of 730 cases
of breast cancer were determined based on the expression
levels of ERα, PR and Her-2 (Table 2). A total of 545 cases
of breast cancer were identified with molecular subtypes,
including 202 cases (37.1%) of lumina A type (ERα+, PR+,
Her-2-), 147 cases (27.0%) of luminal B type (ERα+, PR+,
Her-2+), 95 cases (17.4%) of Her-2 over-expression type
(ERα-, PR-, Her-2+) and 101 cases (18.5%) of basal like type
(ERα-, PR-, Her-2-). Then we analyzed the expression of
ERβ in different molecular subtypes. As shown in Table 2,
the ERβ expression was significantly different among differ-
ent molecular subtypes of breast cancer (χ2 = 20.543, P <
0.05). In cases with ERβ (−) expression, Lumina A type
breast cancer had the highest proportion (34.2%, 97/284)
while Her-2 over-expression type (17.3%, 49/284) and
basal like type (22.2%, 63/284) had the lowest proportion.
The basal like type had higher proportion of cases with
ERβ (+++) expression (20.8%, 11/53) than that of cases
with ERβ (+) expression (13.0%, 30/154) and ERβ (++) ex-
pression (13.0%, 7/54). Therefore, ERβ was differentially
expressed in different molecular subtypes of breast cancer.
Correlation analysis of ERβ, ERα, PR and Her-2 expression
To analyze the correlation of ERβ, ERα, PR and Her-2 ex-
pression, Spearman’s Rank-order correlation was performed
in 730 cases of breast cancer patients. The results wereer tissue. Immunohistochemistry was performed to detect ERβ, ERα, PR
ranules were positive cells. Scale bar, 100 μm. (A) ERβ negative tissue
positive rate of < 10%). (C) ERβ positive expression tissue (ERβ (++), cancer
ue (ERβ (+++), cancer cells with a positive rate of > 50%). (E) ERα negative
Her-2 negative tissue. (J) Her-2 positive tissue.
Table 2 Expression of ERβ in different molecular subtypes of breast cancer
Total
cases
ERβ (-) ERβ (+) ERβ (++) ERβ (+++) χ2 P
Cases (%) Cases (%) Cases (%) Cases (%)
Luminal A type 202 97 (48.0) 66 (32.7) 27 (13.4) 12 (5.9)
20.543 0.015*
Luminal B type 147 75 (51.0) 38 (25.9) 11 (7.5) 23 (15.6)
Her-2 over-expression type 95 49 (51.6) 30 (31.6) 9 (9.5) 7 (7.4)
Basal like type 101 63 (62.4) 20 (19.8) 7 (6.9) 11 (10.9)
Note: Pearson chi-square test, *P < 0.05.
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was positively correlated (P < 0.05). ERα expression and
Her-2 expression was negatively correlated (P < 0.01). And,
there was a negative correlation between PR expression
and Her-2 expression (P < 0.05). A positive correlation was
found between ERα expression and PR expression (P <
0.01). However, no correlation between ERβ expression and
ERα expression or PR expression was identified (P > 0.05).
The tumor-free survival rate of the patients with positive
expression of ERβ is significantly decreased
To investigate the effect of ERβ expression on survival
of breast cancer patients, the accumulative tumor-free
survival rate was analyzed by Kaplan-Meier method and
the differences in survival time were analyzed by Log-
Rank test. The survival curve of ERβ negative and posi-
tive expression patients (including ERβ (+), ERβ (++)
and ERβ (+++) ) was shown in Figure 2. The median
tumor-free survival rate in patients with negative ERβ
expression was 9.341 years. Meanwhile, the median
tumor-free survival rate in ERβ positive expression pa-
tients was 7.850 years, significantly lower than that in
low ERβ expression patients (Log-rank test, χ2 = 10.748,
P < 0.01). This result suggests that patients with positive
ERβ expression had shorter tumor-free survival time and
poor prognosis.
Analysis of prognostic factors for breast cancer
We also analyzed the prognostic factors for breast cancer
by the Cox multivariate analysis. The analyzed factors in-
cluded clinical stage, ERβ expression, ERα expression, PR
expression, Her-2 expression and postoperative chemo-
therapy, radiotherapy and endocrine therapy. As shown in
Table 4, clinical stage I was a risk factor for breast cancerTable 3 Correlation analysis of ERβ, ERα, PR and
Her-2 expression
ERβ ERα PR Her-2
ERβ 1 0.021 0.05 0.078*
ERα 0.021 1 0.540** -0.101**
PR 0.05 0.540** 1 -0.086*
Her-2 0.078* -0.101** -0.086* 1
Note: Spearman’s Rank-order correlation, *P < 0.05, **P < 0.01.prognosis, with OR value = 0.164 and P = 0.000. Clinical
stage II was also a risk factor for breast cancer prognosis,
with OR value = 0.408 and P = 0.001. And, the OR value
and P value of ERβ expression was 0.481 and 0.016, re-
spectively, indicating that ERβ expression was a prognostic
risk factor for breast cancer. In addition, postoperative
chemotherapy was also a prognostic risk factor for breast
cancer, with OR value = 0.334 and P = 0.001. However,
ERα expression, PR expression, Her-2 expression, radio-
therapy and endocrine therapy were not independent
prognosis factors. Therefore, the independent prognostic
risk factors for breast cancer included clinical stage, ERβ
expression and postoperative chemotherapy.
Discussion
Breast cancer is a common malignancy in women, with
high mortality rate [13]. Identification of biomarkers for
early detection and new therapeutic targets of breast
cancer helps to reduce the morbidity of this frequent
pathology in women. To date, several breast markers
have been postulated, such as ER (ERα and ERβ), PR,
Her-2, BRCA1 (breast cancer susceptibility gene) and β1
integrin [14-16]. Among them, the role of ERβ in breast
cancer prognosis is still controversial. In this study, the
expression of ERβ in different molecular subtypes
of breast cancer was compared. Our result showed that
the expression level of ERβ had significant difference
(P < 0.05) in the four molecular subtypes of breast can-
cer. In ERβ negative expression group, the proportion of
luminal A type was significantly higher than the other
three subtypes while the proportion of Her-2 overex-
pression type and basal like type was the lowest. Due to
its strong invasive ability and metastasis ability, the basal
like type is an independent prognostic factor of distant
metastasis [17]. In this study, the basal like type had
higher proportion of cases with ERβ (+++) expression,
indicating that overexpression of ERβ may suggest poor
prognosis of breast cancer.
Her-2 is considered to be an oncogene that is closely
related to the development of breast cancer [18]. It is in-
volved in the regulation of cell proliferation and differen-
tiation, and its over-expression indicates high degree of
malignancy, high recurrence rate, strong invasion and
metastasis and poor prognosis. In this study, ERα and
Figure 2 Survival analysis of breast cancer patients with negative and positive ERβ expression. Kaplan-Meier survival curve was displayed.
The differences in survival time were analyzed by Log-Rank test. The patients (730 cases) were followed up for 2 to 10 years. During the follow-up time,
21 patients were censored. Patients died of other diseases, lost to follow-up at the time of last contact or before study cut-off were censored.
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(P < 0.01). PR expression and Her-2 expression was
negatively related (P < 0.05). ERα expression and PR ex-
pression was significantly positively related (P < 0.01).
These results were consistent with previous reports [19].
Moreover, ER and PR might be associated with Her-2
signal transduction pathway [20]. ERα in combination
with estrogen could inhibit the expression of Her-2.
Her-2 expression is up-regulated when ERα expression is
down-regulated. Chung et al. [21] also found that the Her-2
expression was directly related with ERα expression. How-
ever, the role of ERβ in breast cancer and whether it could
be used as a prognosis indicator of breast cancer are still
controversial. Most studies suggest that ERβ is positively
correlated with epidermal growth factor receptor [22]. ERβ
inhibits apoptosis of tumor cells and thus ERβ positive ex-
pression suggests poor prognosis of breast cancer. How-
ever, some studies indicate that ERβ confers a goodTable 4 Analysis of prognostic factors for breast cancer by Co
Variances Regression coefficient Standard error Wa
Clinical staging 2
Stage I -1.807 0.402 2
Stage II -0.897 0.271 1
ERβ expression -0.732 0.303
ERα expression 0.074 0.286
PR expression 0.518 0.315
Her-2 expression -0.108 0.242
Chemotherapy -1.096 0.326 1
Radiotherapy -0.515 0.270
Endocrine therapy -0.016 0.279
Note: Cox multivariate analysis, *P < 0.05.prognosis of breast cancer [23]. In this study, ERβ and Her-
2 was positively related (P < 0.05), suggesting that positive
expression of ERβ may be a poor indicator of breast cancer
prognosis. This result was consistent with the data reported
by Huang et al. [24]. They found that positive expression of
ERβ indicated poor distant disease-free survival (DDFS) ra-
ther than the overall survival time. ERβ may be related
to distant metastasis of breast cancer and the overall
survival time of the patients with positive ERβ expres-
sion was significantly lower than the ones with negative
ERβ expression.
The cumulative tumor-free survival rate was analyzed
by the Kaplan-Meier method. The cumulative tumor-free
survival rate of the patients with positive ERβ expression
was significantly decreased. The Cox multivariate analysis
showed that ERβ expression, clinical stage and postopera-
tive chemotherapy were independent risk factors for
breast cancer prognosis. The positive ERβ expression wasx multivariate analysis
ld value P value OR value 95.0% confidence intervals
2.570 0.000*
0.205 0.000* 0.164 0.075 0.361
0.976 0.001* 0.408 0.240 0.693
5.834 0.016* 0.481 0.266 0.871
0.067 0.795 1.077 0.615 1.888
2.704 0.100 1.679 0.905 3.115
0.199 0.656 0.898 0.559 1.442
1.337 0.001* 0.334 0.177 0.633
3.648 0.056 0.597 0.352 1.014
0.003 0.954 0.984 0.570 1.700
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in patients with positive ERβ expression. The underlying
mechanisms of the role of ERβ in breast cancer might be
related with the following two aspects. One is that through
binding with ERβ, estrogen can activate G protein which
rapidly inhibits c-Jun N-terminal kinase (JNK) pathway
and apoptosis of breast cancer cells [25]. The other one is
that ERβ could regulate the expression of related genes in
the Wnt signaling pathway [26]. Thus, ERβ could regulate
the cell proliferation and invasion of breast cancer. And
its expression is closely related with the recurrence and
metastasis of breast cancer.
In summary, ERβ was differentially expressed in differ-
ent breast cancer molecular subtypes. And ERβ expres-
sion was positively correlated with Her-2 expression.
The cumulative tumor-free survival time in patients with
negative ERβ expression was longer than the ones with
positive ERβ expression. Multivariate analysis indicates
that ERβ was an independent risk factor for breast can-
cer prognosis. Therefore, we suppose that combined de-
tection of ERβ and ERα would be beneficial to better
assess the proliferation activity of breast cancer and to
improve the accuracy of prognosis evaluation in patients
with breast cancer.
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